Should I Buy HSIC? HSIC 2026 Analysis

Should You Buy Henry Schein Inc (HSIC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

79.720

1 Day change

3.53%

52 Week Range

81.350

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (HOLD). Price bounced to ~~$75.26, but it’s still below the key pivot/resistance (~~$76.13) with momentum not yet convincingly bullish.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Options positioning is mixed (bullish OI structure but bearish volume skew), and the pattern-based projection flags elevated downside risk over the next month.
If you must act immediately (impatient entry), HSIC is not the best “buy-now” setup; the cleaner buy would be on a breakout/hold above ~~$76.13 or a pullback toward support (~~$73.70).

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.484) but contracting (bearish momentum is fading, not reversed).
RSI: RSI(6) ~46.6 (neutral; no strong buy signal).
Moving averages: Converging MAs suggest consolidation rather than a clear uptrend.
Key levels: Pivot ~76.13 (overhead decision level). Support S1 ~73.70 then S2 ~72.20. Resistance R1 ~78.56 then R2 ~80.06.
Price context: +2.90% close suggests short-term rebound, but price remains below pivot—still “prove it” territory.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment read: Low OI put-call (0.3) is typically bullish (more calls outstanding), but put-heavy volume (put/call volume 4.5) suggests near-term caution/hedging or bearish speculation.
Volatility: IV30 ~31.48 vs historical vol ~23.35 (options pricing in elevated near-term moves/uncertainty, consistent with earnings on 2026-02-24).
IV percentile: ~75.7 (relatively high vs its recent range), implying options are expensive and the market is more jumpy than usual.
Flow intensity: Today’s option volume is very low in absolute terms (11 contracts), so sentiment signals should be treated as “directional but not decisive.”

Technical Summary

Sell

Buy

Positive Catalysts

- Upcoming earnings catalyst: QDEC 2025 earnings on 2026-02-24 (pre-market) can re-rate the stock if results/guide beat expectations.
- Analyst tone improving: Barclays initiated with Overweight; Mizuho raised price target—incrementally supportive.
- Top-line growth: Latest reported quarter showed revenue +5.2% YoY, indicating demand resilience.

Neutral/Negative Catalysts

- Margin pressure: Gross margin down ~1.98% YoY in 2025/Q3—profitability trend is a key overhang.
- Mixed options tape: Put volume dominates today (bearish near-term sentiment), despite bullish-ish OI structure.
- Technical positioning: Price still below pivot (~76.13); failure to reclaim it can invite another retest of ~$73.70 support.
- Pattern-based outlook: Similar-candlestick model suggests -10.53% over the next month, implying unfavorable near-term risk/reward for an “enter now” approach.
- No fresh news tailwinds in the past week to extend momentum.

Financial Performance

Latest quarter (2025/Q3):
- Revenue: $3.339B, +5.20% YoY (steady growth)
- Net income: $101M, +2.02% YoY (slower than revenue)
- EPS: $0.83, +6.41% YoY (better than net income growth, likely helped by mix/controls)
- Gross margin: 28.69%, down ~1.98% YoY (key negative trend)
Overall: growth is positive, but margin compression suggests quality of growth is mixed going into the next earnings event.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend:
- 2025-12-08: Barclays initiated Overweight, PT $86 (bullish initiation)
- 2026-01-20: Mizuho Neutral, PT raised to $81 from $74 (more constructive, but still not a full buy)
Wall Street pros: improving sentiment and higher targets; expectation for a better dental industry backdrop.
Wall Street cons: at least one major firm remains Neutral; margin pressure and execution risk likely keep conviction from being uniformly bullish.
Influential/insider/political activity: Insiders neutral; hedge funds neutral; no recent Congress trading data available.

10 Analyst Rating

Wall Street analysts forecast HSIC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSIC is 76.78 USD with a low forecast of 58 USD and a high forecast of 90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

2 Sell

Moderate Buy

Current: 77.000

Low

Averages

76.78

High

Current: 77.000

Low

Averages

76.78

High

Mizuho

Steven Valiquette

Neutral

maintain

$74 -> $81

AI Analysis

2026-01-20

Reason

Mizuho

Steven Valiquette

Price Target

$74 -> $81

AI Analysis

2026-01-20

maintain

Neutral

Reason

Mizuho analyst Steven Valiquette raised the firm's price target on Henry Schein to $81 from $74 and keeps a Neutral rating on the shares. Mizuho's annual dental industry survey is more positive than prior years, the analyst tells investors in a research note. The firm upped targets in the dental group as part of its 2026 outlook.

Barclays

Overweight

initiated

$86

2025-12-08

Reason

Barclays

Price Target

$86

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Henry Schein with an Overweight rating and $86 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HSIC

Unlock Now

HSIC Should I Buy

HSIC Should I Buy

Should You Buy Henry Schein Inc (HSIC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch